|
1
|
Doorbar J: Molecular biology of human
papillomavirus infection and cervical cancer. Clin Sci (Lond).
110:525–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomizawa Y, Kohno T, Kondo H, et al:
Clinicopathological significance of epigenetic inactivation of
RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res.
8:2362–2368. 2002.PubMed/NCBI
|
|
3
|
Dammann R, Li C, Yoon JH, Chin PL, et al:
Epigenetic inactivation of a RAS association domain family protein
from the lung tumour suppressor locus 3p21.3. Nat Genet.
25:315–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann U, Langer F, Feist H, et al:
Quantitative assessment of promoter hypermethylation during breast
cancer development. Am J Pathol. 160:605–612. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing M, Cohen Y, Mambo E, et al: Early
occurrence of RASSF1A hypermethylation and its mutual exclusion
with BRAF mutation in thyroid tumorigenesis. Cancer Res.
64:1664–1668. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yegnasubramanian S, Kowalski J, Gonzalgo
ML, et al: Hypermethylation of CpG islands in primary and
metastatic human prostate cancer. Cancer Res. 64:1975–1986. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuzmin I, Liu L, Dammann R, et al:
Inactivation of RAS association domain family 1A gene in cervical
carcinomas and the role of human papillomavirus infection. Cancer
Res. 63:1888–1893. 2003.PubMed/NCBI
|
|
8
|
Cohen Y, Singer G, Lavie O, et al: The
RASSF1A tumor suppressor gene is commonly inactivated in
adenocarcinoma of the uterine cervix. Clin Cancer Res. 9:2981–2984.
2003.PubMed/NCBI
|
|
9
|
Kim SH, Juhnn YS, Kang S, et al: Human
papillomavirus 16 E5 up-regulates the expression of vascular
endothelial growth factor through the activation of epidermal
growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci.
63:930–938. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tan S, Hougardy BM, Meersma GJ, et al:
Human papilloma virus 16 E6 RNA interference enhances cisplatin and
death receptor-mediated apoptosis in human cervical carcinoma
cells. Mol Pharmacol. 81:701–709. 2012. View Article : Google Scholar
|
|
11
|
Vassallo J, Derchain SF, Pinto GA,
Martinez EZ, Syrjänen KJ and Andrade LA: High risk HPV and p53
protein expression in cervical intraepithelial neoplasia. Int J
Gynaecol Obstet. 71:45–48. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tian Y, Hou Y, Zhou X, et al: Tumor
suppressor RASSF1A promoter: p53 binding and methylation. PLoS One.
6:e170172011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Preethy CP, Padmapriya R, Periasamy VS, et
al: Antiproliferative property of n-hexane and chloroform extracts
of Anisomeles malabarica (L). R Br in HPV16-positive human
cervical cancer cells. J Pharmacol Pharmacother. 3:26–34. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matallanas D, Romano D, Yee K, et al:
RASSF1A elicits apoptosis through an MST2 pathway directing
proapoptotic transcription by the p73 tumor suppressor protein. Mol
Cell. 27:962–975. 2007. View Article : Google Scholar
|
|
15
|
Shivakumar L, Minna J, Sakamaki T, et al:
The RASSF1A tumor suppressor blocks cell cycle progression and
inhibits cyclin D1 accumulation. Mol Cell Biol. 22:4309–4318. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song MS, Song SJ, Ayad NG, et al: The
tumour suppressor RASSF1A regulates mitosis by inhibiting the
APC-Cdc20 complex. Nat Cell Biol. 6:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fen J, Yoshinouchi M, Nakamura K, et al:
Eradication of HPV post-surgical treatments, its correlation with
specific types, types of surgery and the physical status. Oncol
Rep. 12:375–379. 2004.PubMed/NCBI
|
|
18
|
Bosch FX, Manos MM, Muñoz N, et al:
Prevalence of human papillomavirus in cervical cancer: a worldwide
perspective. International Biological Study on Cervical Cancer
(IBSCC) Study Group. J Natl Cancer Inst. 87:796–802. 1995.
View Article : Google Scholar
|
|
19
|
Pöllänen R, Soini Y, Vähäkangas K, et al:
Aberrant p53 protein expression in cervical intra-epithelial
neoplasia. Histopathology. 23:471–474. 1993.
|
|
20
|
Boulet G, Horvath C, Vanden Broeck D, et
al: Human papilloma virus: E6 and E7 oncogenes. Int J Biochem Cell
Biol. 39:2006–2011. 2007. View Article : Google Scholar
|
|
21
|
Kuzmin I, Gillespie JW, Protopopov A, et
al: The RASSF1A tumor suppressor gene is inactivated in prostate
tumors and suppresses growth of prostate carcinoma cells. Cancer
Res. 62:3498–3502. 2002.PubMed/NCBI
|
|
22
|
Rong R, Jiang LY, Sheikh MS, et al:
Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates
RASSF1A-mediated microtubule interaction and M-phase cell cycle
regulation. Oncogene. 26:7700–7708. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ahmed-Choudhury J, Agathanggelou A, Fenton
SL, et al: Transcriptional regulation of cyclin A2 by RASSF1A
through the enhanced binding of p120E4F to the cyclin A2 promoter.
Cancer Res. 65:2690–2697. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song SJ, Song MS, Kim SJ, et al: Aurora A
regulates prome-taphase progression by inhibiting the ability of
RASSF1A to suppress APC-Cdc20 activity. Cancer Res. 69:2314–2323.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baksh S, Tommasi S, Fenton S, et al: The
tumor suppressor RASSF1A and MAP-1 link death receptor signaling to
Bax conformational change and cell death. Mol Cell. 18:637–650.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rabizadeh S, Xavier RJ, Ishiguro K, et al:
The scaffold protein CNK1 interacts with the tumor suppressor
RASSF1A and augments RASSF1A-induced cell death. J Biol Chem.
279:29247–29254. 2004. View Article : Google Scholar : PubMed/NCBI
|
